Uprosertib (GSK2141795) is an AKT inhibitor [185] which was investigated in a non-randomized clinical study that included patients with solid tumors, including PC patients in advanced stages, who were administered uprosertib in continuous/intermittent combination with trametinib [186]. The gene discussed is AKT1; the disease is pachyonychia congenita.